Skip to Content

Conference Program

Wednesday, Feb. 8, 2012

7:30 a.m.   Registration and Continental Breakfast

8:25 – 8:40 a.m.   Welcome

Edward T.H. Yeh
The University of Texas MD Anderson Cancer Center, Houston, TX

8:40 - 10:25 a.m.   Session I 

Moderator: Edward T.H. Yeh
The University of Texas MD Anderson Cancer Center, Houston, TX

8:40 - 9:05 — Insights to SUMO-substrate recognition    
Christopher D. Lima
Sloan-Kettering Institute, New York, NY

9:05 -9:30 — Phosphorylation-regulated SUMOylation    
Xin-Hua Feng
Baylor College of Medicine, Houston, TX

9:30 - 9:55 — Molecular insights into Daxx SUMOylation regulated by phosphorylation and acetylation    
Hsui-Ming Shih
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan 

9:55 - 10:10 — SUMO Signaling Networks Uncovered by Mass Spectrometry    
Alfred Vertegaal
Leiden University Medical Center, Leiden, the Netherlands

10:10 – 10:25 — A SNAP-SUMO system for analysis of global  SUMOylation changes during keratinocyte differentiation    
Van Wilson
Texas A&M Health Science Center, College Station, TX

10:25 - 10:55 a.m.   Break

10:55 a.m. – 12:30 p.m.   Session II

Moderator: Christopher D. Lima
Sloan-Kettering Institute, New York, NY

10:55 - 11:20 — Regulating cellular activities through SUMO proteases    
Mary Dasso
National Institutes of Health, LGRD, NICHD, Bethesda, MD

11:20 - 11:45 — SUMOylation in intestinal homeostasis and cancer    
Anne Dejean
Institut Pasteur, Paris, France

11:45 – 12:00 — SUMO-specific Protease 7 regulates heterochromatin protein 1 alpha to promote senescence or epithelial-mesenchymal transition in breast cancer cells    
Tasneem Bawa-Khalfe
The University of Texas MD Anderson Cancer Center, Houston, TX

12:00 – 12:15 — Desumoylation in C. elegans epithelial morphogenesis    
Limor Broday
Tel Aviv University, Tel Aviv, Israel

12:15 – 12:30 — Characterization of the role of SUMO in the control of protein synthesis in response to stress    
Felicity Z. Watts
University of Sussex, Brighton, UK

12:30 a.m. - 1:30 p.m.   Lunch

1:30 - 2:55 p.m.   Session III

Moderator: Mary Dasso
National Institutes of Health, LGRD, NICHD, Bethesda, MD

1:30 - 1:55 — Regulation of chromatin structure and transcription by SUMO    
Grace Gill
Tufts University School of Medicine, Boston, MA

1:55 – 2:10 — A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma    
Brigitte Bressac-de Paillerets
Institut de Cancérologie Gustave Roussy, Villejuif, France

2:10 – 2:25 — Modifying NR5A (SF-1, LRH-1) transcriptional programs by SUMOylation in development and disease    
Emily Faivre
University of California San Francisco, San Francisco, CA

2:25 - 2:40 — Examining the role of SUMOylation in the function of a C. elegans T-box transcription factor TBX-2    
Paul Huber
University of Illinois at Chicago, Chicago, IL

2:40 - 2:55 — Ubiquitylation of the mineralocorticoid receptor is regulated by aldosterone-induced phosphorylation    
Olivier Staub
University of Lausanne, Lausanne, Switzerland

2:55 - 3:25 p.m.   Break

3:25 - 5:00 p.m.   Session IV

Moderator: Grace Gill
Tufts University School of Medicine, Boston, MA

3:25 - 3:50 — SUMOylation in cardiac development and disease
Robert Schwartz
University of Houston, Houston, TX

3:50 - 4:05 — SUMO1-dependent regulation of SR calcium ATPase Pump, SERCA2a in heart failure
Changwon Kho
Mount Sinai School of Medicine, New York, NY

4:05 – 4:30 — SENP3: Links oxidation and ubiquitination with SUMOylation
Jing Yi
Shanghai Jiao Tong University School of Medicine, Shanghai, China

4:30 - 4:45 — PML Nuclear Bodies: a ROS-induced shell of cross-linked PML for SUMOylation/degradation control    
Valérie Lallemand-Breitenbach 
Institut Universitaire Hématologie, Université Paris Diderot, Paris, France

4:45 – 5:00 — C-terminal domain SUMOylation of DNA Topoisomerase IIα recruits checkpoint complex on centromeres
Yoshiako Azuma
University of Kansas, Lawrence, KS

 

5:15 – 8:15 p.m.   Session V
Poster Session, Reception and Dinner

5:15 - 6:45 — Poster Session, Even Side, and Reception
6:15 - 7:15 — Dinner Buffet
6:45 - 8:15 — Poster Session, Odd Side 

 

Thursday, Feb. 9, 2012

7:30 a.m.   Registration and Continental Breakfast

8:30 - 10:20 a.m.   Session VI

Moderator: Ze'ev Ronai
The Burnham Institute, La Jolla, CA

8:30 – 9:00 — Challenging the polyubiquitin degradation signal: The proteasome can do with less
Aaron Ciechanover    
Technion-Israel Institute of Technology, Haifa, Israel

 9:00 – 9:25 — Mechanisms of proteasome assembly, activation, and function
George N. DeMartino
The University of Texas Southwestern Medical Center, Dallas, TX

9:25 – 9:50 — Regulating mitochondrial dynamics by the ubiquitin-proteasome system
Allan Weissman
National Cancer Institute, Frederick, MD

9:50 – 10:05 — Epsin-ENTH domain is a bona fide ubiquitin binding domain
Gali Prag
Tel Aviv University, Tel Aviv, Israel

10:05 – 10:20 — Int6 impacts breast cancer by regulating both proteasomal degradation and translation initiation
Eric Chang
Baylor College of Medicine, Houston, TX

10:20 – 10:50 a.m.   Break

10:50 a.m. – 12:45 p.m.  Session VII

Moderator: Avram Hershko
Technion-Israel Institute of Technology, Haifa, Israel

10:50 - 11:15 — Mechanisms of SCF-mediated regulation of NF-κB2 and BCL6: relevance in B-cell neoplasms
Michele Pagano
New York University School of Medicine, New York, NY

11:15 – 11:40 — Siah2 in hypoxia and cancer
Ze'ev Ronai
The Burnham Institute, La Jolla, CA

11:40 – 12:05 — Non-canonical regulation of gene expression via hypoxia-inducible factor
Michael Ohh
University of Toronto, Toronto, ON, Canada

12:05 – 12:30 — Pc2contributes to pathogenesis of hepatocellular carcinoma via SUMOylating HIF-1α and inducing angiogenesis    
Guo-Qiang Chen    
Shanghai Jiao Tong University School of Medicine, Shanghai, China

12:30 – 12:45 — KLHL20 mediates PML ubiquitination to potentiate HIF-1 signaling and prostate cancer progression     
Ruey-Hwa Chen    
Institute of Biomedical Chemistry, Academia Sinica, Taipei, Taiwan 

12:45 – 1:45 p.m.  Lunch

1:45 – 3:35 p.m.  Session VIII

Moderator: Aaron Ciechanover
Technion-Israel Institute of Technology, Haifa, Israel

1:45 – 2:10 — Ubl protein activating enzymes    
Neil Bence
Millennium: The Takeda Oncology Company, Cambridge, MA

2:10 – 2:35 — Targeting SUMOylation for the development of research tools and therapeutics    
Yuan Chen
Beckman Research Institute of the City of Hope, Duarte, CA

2:35 – 2:50 — Small-molecule inhibitors of de-ubiquitinating enzymes for cancer treatment    
Martina Bazzaro
University of Minnesota Twin Cities, Minneapolis, Minnesota

2:50 – 3:05 — Novel selective inhibitor of POSH for the potential treatment of cancer and inflammatory diseases    
Ety Klinger
Proteologics LTD, Rehovot, Israel

3:05 – 3:20 — Artificial SUMO Ligases - An innovative tool to study the effects of SUMOylation on specific targets    
German Rosas-Acosta
The University of Texas at El Paso, El Paso, TX

3:20 – 3:35 — Development of small molecules that induce IAP-mediated ubiquitylation and proteasomal degradation    
Mikihiko Naito
National Institute of Health Sciences, Tokyo, Japan

3:35 – 4:05 p.m.  Break

4:05 – 5:40 p.m.   Session IX

Moderator: Allan Weissman
National Cancer Institute, Frederick, MD

4:05 – 4:30 — Ubiquitin signaling in the RIG-I anti-viral innate immunity pathway     
Zhijian 'James' Chen     
University of Texas Southwestern Medical Center, Dallas, TX

4:30 – 4:55 — SENP1 and interferon-γ signaling     
Jinke Cheng
Shanghai Jiao Tong University School of Medicine, Shanghai, China     

4:55 – 5:10 — SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation    
Thang Nguyen
The University of Texas MD Anderson Cancer Center, Houston, TX

5:10 – 5:25 — Inactivation of USP18 isopeptidase function enhances ISGylation and antiviral activity in vivo    
Klaus-Peter Knobeloch
University Freiburg, Freiburg, Germany

5:25 – 5:40 — PML and PMLRARα interact with Fas to regulate  Fas-mediated apoptosis in vivo    
Felipe Samaniego
The University of Texas MD Anderson Cancer Center, Houston, TX

 

Friday, Feb. 10, 2012

7:30 a.m.   Registration and Continental Breakfast

8:30 – 8:40 — Welcome Remarks    
Ronald DePinho, President
The University of Texas MD Anderson Cancer Center, Houston, TX

8:40 - 10:30 a.m.   Session X

Moderator: Michele Pagano
New York University School of Medicine, New York, NY

8:40 – 9:10 — Regulation of APC/C ubiquitin ligase in the cell cycle    
Avram Hershko
Technion-Israel Institute of Technology, Haifa, Israel

9:10 – 9:35  — Identification of Cullin Ring ligase substrates    
Steve Elledge 
Harvard Medical School, Boston, MA

9:35 – 10:00 — Metabolic regulation by ubiquitin ligases    
Cam Patterson 
The University of North Carolina at Chapel Hill, Chapel Hill, NC

10:00 – 10:15 — The glomuvenous malformation protein glomulin binds Rbx1 and regulates CRL-mediated turnover of Fbw7    
James DeCaprio 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

10:15 – 10:30 — Distinct E3 ligases regulate Akt ubiquitination, activation and cancer development    
Hui-Kuan Lin 
The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 – 11:00 a.m.   Break

11:00 a.m. – 12:25 p.m.   Session XI

Moderator: Alan D’Andrea 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

11:00 – 11:25 — Crosstalk between the ubiquitin and SUMO pathways     
Tony Hunter     
Salk Institute for Biological Studies , La Jolla, CA

11:25 – 11:40 — Targeting SUMOylation for degradation during DNA damage response     
David Ann
Beckman Research Institute of the City of Hope, Duarte, CA

11:40 – 11:55 — The role of SUMO targeted ubiquitin ligase in transcriptional activation     
Amir Orian
Technion-Israel Institute of Technology, Haifa, Israel

11:55 – 12:10 — RNF4 regulates BLM in replication-fork stability     
Nathan Ellis     
University of Illinois at Chicago, Chicago, IL

12:10 – 12:25 — HSP27 selectively targets ΔF508 CFTR for degradation via the SUMO pathway     
Raymond Frizzell
University of Pittsburgh, Pittsburgh, PA

12:25 – 1:25 p.m.   Lunch

1:25 – 3:10 p.m.    Session XII

Moderator: Tony Hunter
Salk Institute for Biological Studies, La Jolla, CA

1:25 – 1:50 — Regulation of the Fanconi anemia pathway by ubiquitin and SUMO    
Alan D’Andrea     
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

1:50 – 2:15 — RNF4 STUbL in the DNA damage response     
Yaron Galanty
The Gurdon Institute, University of Cambridge, Cambridge, UK

2:15 – 2:40 — The role of SUMOylation in DNA repair and replication stress response pathways     
Michael Matunis
Johns Hopkins University, Baltimore, MD

2:40 – 2:55 — SENP6 in DNA replication and repair    
Hong Dou
The University of Texas MD Anderson Cancer Center, Houston, TX

2:55 – 3:10 — USP28 is a modulator of the Fanconi anemia pathway and DNA double-strand break repair    
Celine Jacquemont
Fred Hutchinson Cancer Research Center, Seattle, WA

3:10 – 3:40 p.m.   Break

3:40 – 5:10 p.m.   Session XIII

Moderator: George DeMartino
The University of Texas Southwestern Medical Center, Dallas, TX

3:40 – 3:55 — SUMOylation of the α-kleisin subunit of cohesin is necessary for DNA damage-induced cohesion    
Luis Aragon
MRC Clinical Sciences Centre, Imperial College, London, UK

3:55 – 4:10 Chromatin remodeling-assisted ubiquitylation     
Nico Dantuma
Karolinska Institutet, Stockholm, Sweden

4:10 – 4:25 —Roles of COP9 signalosome in cancer     
Mong-Hong Lee
The University of Texas MD Anderson Cancer Center, Houston, TX

4:25 – 4:40 — DEN1 and COP9 signalosome interaction balances cellular deneddylase activity with developmental functions    
Gerhard Braus
Institute of Microbiology and Genetics, Goettingen, Germany

4:40 – 4:55 — Expression of COP9 signalosome subunits is coordinated by miRNAs: Relevance for tumor therapy    
Wolfgang Dubiel
Universitätsmedizin Berlin, Berlin, Germany

4:55 – 5:10 — COP9 signalosome and deubiquitinylases control NF-kB/RelA transcriptional activity    
Michael Naumann
Otto von Guericke University, Magdeburg, Germany

5:10 – 5:30 p.m.   Break

5:30 – 8:30 p.m.   Session XIV
Poster Session, Reception and Dinner

5:30 - 7:00 — Poster Session, Even Side, and Reception
6:30 - 7:30 — Dinner Buffet
7:00 - 8:30 — Poster Session, Odd Side

 

Saturday, Feb. 11, 2012

7:30 a.m.   Continental Breakfast

8:30 - 10:00 a.m.   Session XV

Moderator: Cam Patterson
The University of North Carolina at Chapel Hill, Chapel Hill, NC

8:30 – 8:55 —Ubiquitin ligases involved in muscle atrophy and protection against neurodegeneration.     
Alfred Goldberg
Harvard Medical School, Boston MA

8:55 – 9:20 — The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling    
David Glass
Novartis Institutes for BioMedical Research Inc., Cambridge, MA

9:20 – 9:45 — Chaperone-mediated protein degradation as a modulator of gene expression.    
Henry Epstein
University of Texas Medical Branch at Galveston, Galveston, TX

9:45 – 10:00 — Sphingosine-1-phosphate: A cofactor for E3 ubiquitin ligases    
Sarah Spiegel
Virginia Commonwealth University School of Medicine, Richmond, VA

10:00 –10:20 a.m.   Break

10:20 a.m. – 12:00 noon    Session XVI

Moderator: Michael Matunis
Johns Hopkins University, Baltimore, MD

10:20 – 10:45 — SUMO and sudden death     
Edward T.H. Yeh
The University of Texas MD Anderson Cancer Center, Houston, TX

10:45 – 11:00 — MeCP2 interacting partners in development and Rett Syndrome     
Mary E. Donohoe
Weill Cornell Medical College, White Plains, NY

11:00 – 11:15 — SUMO1 transgenic mouse models and neurodegenerative disease     
Paul Fraser
University of Toronto, Toronto, ON, Canada

11:15 – 11:30 — Massive activation of the SUMO conjugation pathway in human brain tumors; implications for new therapeutic strategies    
Wulf Paschen
Duke University Medical Center, Durham, NC

11:30 – 11:45 — Deconstructing how neurons react to ATP deficits: Ubiquitination, proteasomes, IDPs & nannies    
Maria E. Figueiredo-Pereira    
Hunter College, City University of New York, New York, NY

11:45 – 12:00 — INNO-406, a second generation Abl-inhibitor, as a Parkinson’s disease therapy    
Syed Imam
US FDA/National Center for Toxicological Research, Jefferson, AZ

Closing Comments and Adjourn    
Edward T.H. Yeh
The University of Texas

Box lunch pickup


© 2014 The University of Texas MD Anderson Cancer Center